BRPI0916489A2 - particula tipo vírus (vlp), polinucleotídeo isolado, vetor de expressão, célula procariótica ou eucariótica, composição imunogênica, vacina, método para indução de uma resposta imune contra de chikungunya em um indivíduo e uso de uma partícula tipo vírus - Google Patents
particula tipo vírus (vlp), polinucleotídeo isolado, vetor de expressão, célula procariótica ou eucariótica, composição imunogênica, vacina, método para indução de uma resposta imune contra de chikungunya em um indivíduo e uso de uma partícula tipo vírusInfo
- Publication number
- BRPI0916489A2 BRPI0916489A2 BRPI0916489A BRPI0916489A BRPI0916489A2 BR PI0916489 A2 BRPI0916489 A2 BR PI0916489A2 BR PI0916489 A BRPI0916489 A BR PI0916489A BR PI0916489 A BRPI0916489 A BR PI0916489A BR PI0916489 A2 BRPI0916489 A2 BR PI0916489A2
- Authority
- BR
- Brazil
- Prior art keywords
- virus particle
- chikungunya
- vlp
- prokaryotic
- vaccine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11820608P | 2008-11-26 | 2008-11-26 | |
| US61/118,206 | 2008-11-26 | ||
| US20111808P | 2008-12-05 | 2008-12-05 | |
| US61/201,118 | 2008-12-05 | ||
| PCT/US2009/006294 WO2010062396A2 (en) | 2008-11-26 | 2009-11-24 | Virus like particle compositions and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0916489A2 true BRPI0916489A2 (pt) | 2018-02-06 |
| BRPI0916489B1 BRPI0916489B1 (pt) | 2021-11-09 |
Family
ID=42226306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0916489-8A BRPI0916489B1 (pt) | 2008-11-26 | 2009-11-24 | Partícula do tipo vírus (vlp), composição imunogênica, vacina e uso |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US9353353B2 (pt) |
| EP (2) | EP3613761A1 (pt) |
| CN (2) | CN102317308A (pt) |
| AU (1) | AU2009320287B2 (pt) |
| BR (1) | BRPI0916489B1 (pt) |
| MY (1) | MY161495A (pt) |
| SG (1) | SG171828A1 (pt) |
| WO (1) | WO2010062396A2 (pt) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009231559B2 (en) * | 2008-04-04 | 2015-10-22 | The Trustees Of The University Of Pennsylvania | Consensus sequences of Chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same |
| SG171828A1 (en) | 2008-11-26 | 2011-07-28 | Us Gov Health & Human Serv | Virus like particle compositions and methods of use |
| WO2012095542A1 (es) | 2011-01-10 | 2012-07-19 | Siesta Systems, S.A. | Dispositivo de apoyo parieto-occipital para sujeción lateral de la cabeza en camas con el respaldo elevado |
| US9487563B2 (en) | 2011-01-31 | 2016-11-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Virus-like particles and methods of use |
| EP2688587B2 (en) * | 2011-03-25 | 2023-08-16 | Intervet International B.V. | Salmonid alphavirus vaccine |
| AU2012269907B2 (en) * | 2011-06-17 | 2017-05-18 | Bharat Biotech International Limited | Vaccine composition comprising an inactivated chikungunya virus strain |
| SG11201404711WA (en) * | 2012-02-16 | 2014-09-26 | Vlp Therapeutics Llc | Virus like particle composition |
| DK178233B1 (en) * | 2012-09-17 | 2015-09-14 | Novartis Tiergesundheit Ag | Fiskevaccine |
| EP2712871A1 (en) * | 2012-09-27 | 2014-04-02 | Institut Pasteur | Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications |
| US9701719B2 (en) * | 2012-09-27 | 2017-07-11 | Research Development Foundation | Attenuated Chikungunya virus |
| WO2014196648A1 (en) | 2013-06-03 | 2014-12-11 | Vlp Therapeutics, Llc | Malaria vaccine |
| TWI676636B (zh) | 2013-07-12 | 2019-11-11 | Ｖｌｐ醫療股份有限公司 | 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子 |
| WO2015148768A2 (en) | 2014-03-28 | 2015-10-01 | Tamir Biotechnology, Inc. | Rnase for use in treating or preventing viral infections |
| JP6824154B2 (ja) * | 2014-08-08 | 2021-02-03 | ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ | 修飾エンベロープタンパク質ｅ３を含むウイルス様粒子 |
| US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
| US9642794B2 (en) | 2014-08-18 | 2017-05-09 | Tamir Biotechnology, Inc. | Antiviral pharmaceutical for topical administration |
| CA2960102C (en) | 2014-09-11 | 2023-10-24 | Vlp Therapeutics, Llc | Flavivirus virus like particle |
| KR20180026455A (ko) | 2015-06-15 | 2018-03-12 | 타미르 바이오테크놀로지 인코포레이티드 | 눈의 바이러스 감염의 치료를 위한 의약 |
| US10166281B2 (en) * | 2015-09-04 | 2019-01-01 | Vlp Therapeutics, Llc | Method and composition for modulating immune response |
| FI3393510T3 (fi) * | 2015-12-23 | 2023-03-22 | Valneva Austria Gmbh | Zika-virusrokote |
| WO2017142807A1 (en) | 2016-02-16 | 2017-08-24 | Tamir Biotechnology, Inc. | Treatment or prevention of zika virus infections by administration of a ribonuclease |
| TW202333779A (zh) | 2017-05-08 | 2023-09-01 | 美商磨石生物公司 | 阿爾法病毒新抗原載體 |
| WO2019016756A1 (en) * | 2017-07-21 | 2019-01-24 | Glaxosmithkline Biologicals Sa | ANTIGEN CONSTRUCTS OF CHIKUNGUNYA VIRUSES |
| WO2019057793A1 (en) | 2017-09-21 | 2019-03-28 | Valneva Se | PROCESS FOR THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS COMPRISING THE IMMUNOGENIC VIRUS OF CHIKUNGUNYA CHIKV-DELTA5NSP3 |
| WO2019136316A1 (en) * | 2018-01-04 | 2019-07-11 | Washington University | Compositions and methods for inhibition of alphavirus infection |
| US20220153871A1 (en) | 2018-01-04 | 2022-05-19 | Iconic Therapeutics, Inc. | Anti-Tissue Factor Antibodies, Antibody-Drug Conjugates, and Related Methods |
| WO2020069054A1 (en) * | 2018-09-27 | 2020-04-02 | Texas Tech University System | Stable cell line secreting chikungunya virus (chikv) virus like particles (vlp) for vaccines |
| CN109536464B (zh) * | 2018-12-10 | 2022-06-10 | 中国科学院武汉病毒研究所 | 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用 |
| CA3140019A1 (en) | 2019-05-30 | 2020-12-03 | Gritstone Bio, Inc. | Modified adenoviruses |
| CN114828881A (zh) * | 2019-10-25 | 2022-07-29 | 伊美根特旅行健康公司 | 基孔肯雅病毒样颗粒疫苗及其使用方法 |
| CN116438308A (zh) | 2020-08-06 | 2023-07-14 | 磨石生物公司 | 多表位疫苗盒 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| CA2776391C (en) | 2001-10-01 | 2015-03-31 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Development of a preventive vaccine for filovirus infection in primates |
| AU2003217413A1 (en) | 2002-02-14 | 2003-09-04 | Novavax, Inc. | Method for isolation and purification of expressed gene products in vitro |
| US9045727B2 (en) * | 2002-05-17 | 2015-06-02 | Emory University | Virus-like particles, methods of preparation, and immunogenic compositions |
| CN1913919B (zh) | 2003-09-15 | 2011-10-19 | 美国政府健康及人类服务部 | 基于hiv多进化枝的env的hiv疫苗 |
| EP1736538A1 (en) | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
| WO2008030220A2 (en) * | 2005-08-11 | 2008-03-13 | The Board Of Regents Of The University Of Texas System | Chikungunya virus infectious clones and uses thereof |
| EP2073839B1 (en) * | 2006-09-01 | 2016-10-19 | Bharat Biotech International Limited | A vaccine for chikungunya virus infection |
| SG171828A1 (en) | 2008-11-26 | 2011-07-28 | Us Gov Health & Human Serv | Virus like particle compositions and methods of use |
-
2009
- 2009-11-24 SG SG2011038262A patent/SG171828A1/en unknown
- 2009-11-24 EP EP19183770.7A patent/EP3613761A1/en active Pending
- 2009-11-24 WO PCT/US2009/006294 patent/WO2010062396A2/en active Application Filing
- 2009-11-24 CN CN200980155476XA patent/CN102317308A/zh active Pending
- 2009-11-24 EP EP09829477.0A patent/EP2370455B1/en active Active
- 2009-11-24 BR BRPI0916489-8A patent/BRPI0916489B1/pt active IP Right Grant
- 2009-11-24 AU AU2009320287A patent/AU2009320287B2/en active Active
- 2009-11-24 CN CN201710200081.3A patent/CN107574156A/zh active Pending
- 2009-11-24 MY MYPI2011002376A patent/MY161495A/en unknown
- 2009-11-24 US US13/131,287 patent/US9353353B2/en active Active
-
2016
- 2016-05-03 US US15/145,483 patent/US10369208B2/en active Active
-
2019
- 2019-07-23 US US16/520,113 patent/US11369674B2/en active Active
-
2022
- 2022-06-27 US US17/850,706 patent/US11992523B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SG171828A1 (en) | 2011-07-28 |
| US20230025038A1 (en) | 2023-01-26 |
| EP2370455A4 (en) | 2012-07-04 |
| US20160303221A1 (en) | 2016-10-20 |
| WO2010062396A3 (en) | 2010-12-09 |
| CN102317308A (zh) | 2012-01-11 |
| WO2010062396A2 (en) | 2010-06-03 |
| US11992523B2 (en) | 2024-05-28 |
| EP2370455A2 (en) | 2011-10-05 |
| EP2370455B1 (en) | 2019-07-03 |
| BRPI0916489B1 (pt) | 2021-11-09 |
| US20200085938A1 (en) | 2020-03-19 |
| MY161495A (en) | 2017-04-14 |
| CN107574156A (zh) | 2018-01-12 |
| AU2009320287B2 (en) | 2015-10-08 |
| US11369674B2 (en) | 2022-06-28 |
| US20120003266A1 (en) | 2012-01-05 |
| EP3613761A1 (en) | 2020-02-26 |
| AU2009320287A1 (en) | 2011-06-30 |
| US10369208B2 (en) | 2019-08-06 |
| US9353353B2 (en) | 2016-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0916489A2 (pt) | particula tipo vírus (vlp), polinucleotídeo isolado, vetor de expressão, célula procariótica ou eucariótica, composição imunogênica, vacina, método para indução de uma resposta imune contra de chikungunya em um indivíduo e uso de uma partícula tipo vírus | |
| EP3012322A4 (en) | GENEELED STRAIN VARIANT OF PORCINE PSEUDORABIES VIRUS, VACCINE COMPOSITION, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF | |
| BRPI1012811A2 (pt) | vacinas contra o vírus herpes simplex tipo 2: composições e métodos para obtenção de uma resposta imune | |
| TWI799368B (zh) | 抗ｔｌ１ａ抗原結合蛋白及相關核酸、表現載體、宿主細胞、醫藥組合物、方法及用途 | |
| WO2016073955A3 (en) | Cells lacking b2m surface expression and methods for allogeneic administration of such cells | |
| WO2011103453A3 (en) | Vaccines for use in the prophylaxis and treatment of influenza virus disease | |
| DK3310909T3 (da) | Sammensætninger og fremgangsmåder til at føre proteiner til specifikke loci i genomet | |
| BR112013030321A2 (pt) | composição de vacina, método para preparar a composição de vacina, uso da composição de vacina, método para imunizar um porco, cepa de vacina contra csfv e uso de uma célula no cultivo de uma cepa de vacina contra csfv. | |
| WO2011005799A3 (en) | Rna containing modified nucleotides and use thereof in vaccines | |
| BR112018017307A2 (pt) | molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus | |
| BR112013030396A2 (pt) | polipeptídeo, polinucleotídeo, vetor, célula hospedeira, composição imunogênica, vacina, e, uso de uma composição imunogênica ou de uma vacina | |
| EP2622064A4 (en) | NUCLEOSIDES, NUCLEOTIDES AND MODIFIED NUCLEIC ACIDS AND USES THEREOF | |
| BR112012019757A2 (pt) | composição imunogênica, e, método para induzir uma resposta imune a um polissacarídeo capsular | |
| BR112012008790A2 (pt) | sequências de polinucleotídeos, vetor, proteína de fusão, método de produção de uma proteína de fusão, célula hospedeira, composição imunogênica, método de estímulo ou indução de reação imunológica e usos de uma sequência de polinucleotídeos, de um vetor, de uma proteína de fusão ou de uma composição imunogênica | |
| WO2011163628A3 (en) | Dengue virus (dv) polypeptide sequences, t cell epitopes and methods and uses thereof | |
| CO2017007105A2 (es) | Nuevos virus de tilapia | |
| BRPI1007721A2 (pt) | composição de vacina para induzir uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolada e método para induzir uma resposta imunológica para um rotavírus em um indivíduo | |
| BR112014005404A2 (pt) | citomegalovírus (cmv) defectivo em replicação condicional, composição, métodos para induzir uma resposta imune contra cmv e para preparo de cmv defectivo em replicação condicional, e, uso do cmv defectivo em replicação condicional | |
| HRP20210031T1 (hr) | Pripravci i metode mutantskog faktora viii | |
| SG11202011817WA (en) | Compositions and methods to promote host defense and stimulate, expand, and/or reset t cell repertoires | |
| BR112013016503A2 (pt) | composições e método de vacina de vírus da diarreia viral bovina tipo 1b. | |
| HK1162599A1 (en) | An infectious recombinant cloning system of duck enteritis virus vaccine strain, construction method and use thereof | |
| WO2011057254A3 (en) | Simian adenoviral vector-based vaccines | |
| ZA201603187B (en) | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors | |
| EP2643014A4 (en) | HERPES SIMPLEX TYPE 2 VIRUS VACCINES: COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15I | Others concerning applications: loss of priority | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B12F | Other appeals [chapter 12.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/11/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |